Vor Biopharma (NYSE:VOR) Upgraded at Stifel Nicolaus

Stifel Nicolaus upgraded shares of Vor Biopharma (NYSE:VOR) from a hold rating to a buy rating in a research note published on Wednesday, Marketbeat Ratings reports. They currently have $55.00 price target on the stock.

A number of other brokerages also recently issued reports on VOR. Wedbush reiterated an “outperform” rating on shares of Vor Biopharma in a research report on Thursday, June 26th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Vor Biopharma in a research note on Thursday, August 14th. Five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Vor Biopharma currently has a consensus rating of “Moderate Buy” and an average target price of $113.83.

Vor Biopharma Stock Down 0.6%

NYSE:VOR opened at $33.62 on Wednesday. Vor Biopharma has a 52 week low of $2.62 and a 52 week high of $65.80. The stock has a market capitalization of $212.95 million, a PE ratio of -20.38 and a beta of 2.05. The stock’s 50-day moving average price is $39.06 and its 200-day moving average price is $23.34.

Insider Activity

In related news, major shareholder Reprogrammed Interchange Llc sold 22,363 shares of the business’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $30.80, for a total transaction of $688,780.40. Following the completion of the sale, the insider directly owned 1,639,060 shares in the company, valued at approximately $50,483,048. The trade was a 1.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 756,918 shares of company stock valued at $12,573,293 over the last quarter. Insiders own 0.45% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VOR. Money Concepts Capital Corp grew its holdings in shares of Vor Biopharma by 106.1% during the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company’s stock worth $37,000 after buying an additional 26,535 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after acquiring an additional 58,247 shares in the last quarter. XTX Topco Ltd acquired a new stake in Vor Biopharma in the 2nd quarter valued at about $66,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Vor Biopharma in the first quarter valued at approximately $100,000. Finally, Jane Street Group LLC acquired a new stake in shares of Vor Biopharma in the 1st quarter worth $140,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.